313 related articles for article (PubMed ID: 28393455)
21. Human leukocyte antigen (HLA)-incompatible mean fluorescence intensity-selected platelet products have corrected count increments similar to HLA antigen-matched platelets.
Karafin MS; Schumacher C; Zhang J; Simpson P; Johnson ST; Pierce KL
Transfusion; 2021 Aug; 61(8):2307-2316. PubMed ID: 34075590
[TBL] [Abstract][Full Text] [Related]
22. Utilization of cross-matched or HLA-matched platelets for patients refractory to platelet transfusion.
Rioux-Massé B; Cohn C; Lindgren B; Pulkrabek S; McCullough J
Transfusion; 2014 Dec; 54(12):3080-7. PubMed ID: 24916382
[TBL] [Abstract][Full Text] [Related]
23. ABO-mismatched platelet transfusions: strategies to mitigate patient exposure to naturally occurring hemolytic antibodies.
Josephson CD; Castillejo MI; Grima K; Hillyer CD
Transfus Apher Sci; 2010 Feb; 42(1):83-8. PubMed ID: 20034854
[TBL] [Abstract][Full Text] [Related]
24. A flow cytometric platelet immunofluorescence crossmatch for predicting successful HLA matched platelet transfusions.
Sintnicolaas K; Löwenberg B
Br J Haematol; 1996 Mar; 92(4):1005-10. PubMed ID: 8616059
[TBL] [Abstract][Full Text] [Related]
25. Clinical and quality evaluation of apheresis vs random-donor platelet concentrates stored for 7 days.
Hussein E
Transfus Med; 2015 Feb; 25(1):20-6. PubMed ID: 25808050
[TBL] [Abstract][Full Text] [Related]
26. Platelet crossmatch testing for donor selection.
Slichter SJ
Prog Clin Biol Res; 1982; 88():153-64. PubMed ID: 7100207
[TBL] [Abstract][Full Text] [Related]
27. Transfusion of ABO-mismatched platelets leads to early platelet refractoriness.
Carr R; Hutton JL; Jenkins JA; Lucas GF; Amphlett NW
Br J Haematol; 1990 Jul; 75(3):408-13. PubMed ID: 2201403
[TBL] [Abstract][Full Text] [Related]
28. Validation of HLAMatchmaker algorithm in identifying acceptable HLA mismatches for thrombocytopenic patients refractory to platelet transfusions.
Brooks EG; MacPherson BR; Fung MK
Transfusion; 2008 Oct; 48(10):2159-66. PubMed ID: 18631168
[TBL] [Abstract][Full Text] [Related]
29. ABO-mismatched transfusions are not over-represented in febrile non-haemolytic transfusion reactions to platelets.
Yazer MH; Raval JS; Triulzi DJ; Blumberg N
Vox Sang; 2012 Feb; 102(2):175-7. PubMed ID: 21781126
[TBL] [Abstract][Full Text] [Related]
30. Platelet transfusion therapy for alloimmunized patients: selective mismatching for HLA B12, an antigen with variable expression on platelets.
Schiffer CA; O'Connell B; Lee EJ
Blood; 1989 Aug; 74(3):1172-6. PubMed ID: 2752158
[TBL] [Abstract][Full Text] [Related]
31. An alloimmunized, thrombocytopenic patient successfully transfused with acid-treated, random-donor platelets.
Shanwell A; Sallander S; Olsson I; Gulliksson H; Pedajas I; Lerner R
Br J Haematol; 1991 Nov; 79(3):462-5. PubMed ID: 1751374
[TBL] [Abstract][Full Text] [Related]
32. Platelet transfusion therapy. One-hour posttransfusion increments are valuable in predicting the need for HLA-matched preparations.
Daly PA; Schiffer CA; Aisner J; Wiernik PH
JAMA; 1980 Feb; 243(5):435-8. PubMed ID: 7351763
[TBL] [Abstract][Full Text] [Related]
33. Use of platelet aggregometry in selection of compatible platelet donors.
Wu KK; Hoak JC; Thompson JS; Koepke JA
N Engl J Med; 1975 Jan; 292(3):130-3. PubMed ID: 1196337
[TBL] [Abstract][Full Text] [Related]
34. Response to random apheresis platelets versus HLA-selected platelets versus pooled platelets in HLA-sensitized patients.
Gavva C; Barroso J; Gernsheimer T; Metcalf RA; Warner P; Pagano MB
Transfusion; 2019 Jul; 59(7):2276-2281. PubMed ID: 31032968
[TBL] [Abstract][Full Text] [Related]
35. The role of ABO matching in platelet transfusion.
Heal JM; Rowe JM; McMican A; Masel D; Finke C; Blumberg N
Eur J Haematol; 1993 Feb; 50(2):110-7. PubMed ID: 8440356
[TBL] [Abstract][Full Text] [Related]
36. Pooled platelet product using the Acrodose plus system: evaluation of feasibility, safety and efficacy.
Sawant RB; Marathe AN
Transfus Apher Sci; 2013 Dec; 49(3):535-8. PubMed ID: 24080148
[TBL] [Abstract][Full Text] [Related]
37. Management of bleeding in a multi-transfused patient with positive HLA class I alloantibodies and thrombocytopenia associated with platelet dysfunction refractory to transfusion of cross-matched platelets.
Heuer L; Blumenberg D
Blood Coagul Fibrinolysis; 2005 Jun; 16(4):287-90. PubMed ID: 15870549
[TBL] [Abstract][Full Text] [Related]
38. Management of the Platelet Refractory Patient.
Forest SK; Hod EA
Hematol Oncol Clin North Am; 2016 Jun; 30(3):665-77. PubMed ID: 27113003
[TBL] [Abstract][Full Text] [Related]
39. Transfusion of ABO-nonidentical platelets is not associated with adverse clinical outcomes in cardiovascular surgery patients.
Lin Y; Callum JL; Coovadia AS; Murphy PM
Transfusion; 2002 Feb; 42(2):166-72. PubMed ID: 11896330
[TBL] [Abstract][Full Text] [Related]
40. Safety and efficacy of transfusions of autologous cryopreserved platelets derived from recombinant human thrombopoietin to support chemotherapy-associated severe thrombocytopenia: a randomised cross-over study.
Vadhan-Raj S; Kavanagh JJ; Freedman RS; Folloder J; Currie LM; Bueso-Ramos C; Verschraegen CF; Narvios AB; Connor J; Hoots WK; Broemeling LD; Lichtiger B
Lancet; 2002 Jun; 359(9324):2145-52. PubMed ID: 12090979
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
